Evvy is a female-founded precision women’s health company that builds an AI-powered vaginal healthcare platform grounded in a metagenomic vaginal microbiome test. Since launching in July 2021, Evvy developed the first CLIA/CAP-certified at-home metagenomic (mNGS) vaginal microbiome test that screens bacteria and fungi from a single swab. The company has generated a large longitudinal molecular and phenotypic dataset and runs an integrative, personalized care platform that includes science-backed education and free 1:1 coaching. Evvy ran an IRB-approved study that clinically validated that its platform improves the vaginal microbiome. The company recently added an add-on PCR panel that screens for common STIs and 17 antibiotic-resistance genes with results in three business days and options for immediate prescriptions when necessary. Evvy announced a $14M Series A to scale access to testing and care, leverage AI to discover novel molecular signatures, and validate improved outcomes in fertility, pregnancy, and beyond. Evvy offers an at‑home vaginal microbiome swab kit that uses metagenomic sequencing to profile bacteria and fungi and returns a downloadable, two‑week personalized analysis. The company provides individualized recommendations (rated as ‘‘novel,’’ ‘‘emerging,’’ or ‘‘established’’) and a membership option for repeat testing to track changes. Evvy positions its service as a wellness test (not a regulated medical device) and may consider pursuing FDA clearance in the future. It has priced the single test at $129 and membership tests at $99 each, and is launching across 20 U.S. states with plans to enroll “thousands” of users. The founders have data‑science and product‑design backgrounds and Evvy has recruited OBGYNs and reproductive‑health experts as advisers to support interpretation and research. The company aims to build high‑fidelity datasets and discover female‑specific biomarkers to advance research on outcomes such as pre‑term birth, infertility, STI acquisition and cervical cancer progression.

Total raised

$19M

Funding rounds

2

Latest round

Series A

Latest activity

Sep 2023